Abstract | BACKGROUND: METHODS: Eight FCH heterozygote carriers of the rare -493T allele were compared to 9 matched FCH homozygotes for the wild-type allele in a pilot study. Oral fat loading tests were carried out to measure triglycerides (TG) and apo B48 and B100 in the different fractions of triglyceride-rich lipoproteins (TRLs) before and after treatment with atorvastatin. RESULTS: Before treatment, TG were similar between the -493T allele carriers and non-carriers. In the T-allele carriers, a trend was observed for increased postprandial apo B48 and B100 concentrations in Sf >400 and Sf 60-400 compared to non-carriers. After treatment, fasting and postprandial TG were significantly lowered in carriers of the T allele, but atorvastatin had no effect on postprandial TG in non-carriers. Atorvastatin resulted in similar reductions of apo B48 and B100 in TRLs in both groups. CONCLUSION: The MTP-493G/T polymorphism modulates postprandial apo B48 and apo B100 of TRLs in FCH. Atorvastatin decreases postprandial TG in T-allele carriers with FCH.
|
Authors | Boudewijn Klop, Caroline Verseyden, Josep Ribalta, Juliana Salazar, Luis Masana, Manuel Castro Cabezas |
Journal | Clinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis
(Clin Investig Arterioscler)
2014 Mar-Apr
Vol. 26
Issue 2
Pg. 49-57
ISSN: 1578-1879 [Electronic] Spain |
PMID | 24378322
(Publication Type: Controlled Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2013 Sociedad Española de Arteriosclerosis. Published by Elsevier España. All rights reserved. |
Chemical References |
- Apolipoproteins B
- Carrier Proteins
- Heptanoic Acids
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
- Lipoproteins
- Pyrroles
- Triglycerides
- microsomal triglyceride transfer protein
- Atorvastatin
|
Topics |
- Adult
- Alleles
- Apolipoproteins B
(metabolism)
- Atorvastatin
- Carrier Proteins
(genetics)
- Dose-Response Relationship, Drug
- Female
- Heptanoic Acids
(administration & dosage, pharmacology)
- Humans
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
(administration & dosage, pharmacology)
- Hyperlipidemia, Familial Combined
(drug therapy, genetics)
- Lipoproteins
(blood)
- Male
- Middle Aged
- Pilot Projects
- Polymorphism, Genetic
- Postprandial Period
- Pyrroles
(administration & dosage, pharmacology)
- Triglycerides
(blood)
|